No Data
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
Needham initiated coverage on Praxis Precision Medicines Inc (NASDAQ:PRAX), a clinical-stage biopharmaceutical company, engaged in the development of therapies for central nervous system disorders.The
Needham Initiates Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $145
Needham analyst Ami Fadia initiates coverage on $Praxis Precision Medicines(PRAX.US)$ with a buy rating, and sets the target price at $145.According to TipRanks data, the analyst has a success rate of
Praxis Precision Med Initiated at Buy by Needham
Praxis Precision Med Initiated at Buy by Needham
Express News | Praxis Precision Medicines Inc : Needham Initiates Coverage With Buy Rating; Price Target $145
Express News | Needham Initiates Coverage On Praxis Precision Medicine With Buy Rating, Announces Price Target of $145
Baird Sees Jazz Study Failure as Positive for Rival Praxis
BarfBag : Check out $Pagaya Technologies (PGY.US)$ solid AH